The Genomic, Transcriptomic, and Immunological Landscape of Sodium-glucose cotrasporter 2 in Lung Cancer and Association with Clinical Outcomes | Caris Life Sciences
Portal
Order

MI Cancer Seek™ is now available for clinical ordering. Learn more.

Home / Research / Publications / The Genomic, Transcriptomic, and Immunological Landscape of Sodium-glucose cotrasporter 2 in Lung Cancer and Association with Clinical Outcomes

Publications

Back

The Genomic, Transcriptomic, and Immunological Landscape of Sodium-glucose cotrasporter 2 in Lung Cancer and Association with Clinical Outcomes

– Caris Life Sciences

Poster

Conclusions

  • SLC5A2 expression was associated with a highly altered genomic landscape in AC
  • In specific subgroups, high expression of SLC5A2 was associated with OS and TOT with immunotherapy
Download Publication

Discover
More

  • Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms

    – Caris Life Sciences

    Manuscript

    Abstract Background A recent prospective phase II study (ECOG-ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM)… […]

  • Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer (CRC), CALGB (Alliance)/SWOG 80405 and Real-world Data

    – Caris Life Sciences

    Poster

    Background […]
Learn More

Ready to Get Started on the Journey?

Name(Required)